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Abstract
Background: There is concern that existing models of acute hospital care will become unworkable as the health
service admits an increasing number of frail older people with complex health needs, and that there is inadequate
evidence to guide the planning of acute hospital level services. We aim to evaluate whether geriatrician-led
admission avoidance to hospital at home is an effective alternative to hospital admission.
Methods/Design: We are conducting a multi-site randomised open trial of geriatrician-led admission avoidance
hospital at home, compared with admission to hospital. We are recruiting older people with markers of frailty or
prior dependence who have been referred to admission avoidance hospital at home for an acute medical event.
This includes patients presenting with delirium, functional decline, dependence, falls, immobility or a background
of dementia presenting with physical disease. Participants are randomised using a computerised random number
generator to geriatrician-led admission avoidance hospital at home or a control group of inpatient admission in a
2:1 ratio in favour of the intervention. The primary endpoint ‘living at home’ (the inverse of death or living in a residential
care setting) is measured at 6 months follow-up, and we also collect data on this outcome at 12 months. Secondary
outcomes include the incidence of delirium, mortality, new long-term residential care, cognitive impairment, activities of
daily living, quality of life and quality-adjusted survival, length of stay, readmission or transfer to hospital. We will conduct
a parallel economic evaluation, and a process evaluation that includes an interview study to explore the experiences of
patients and carers.
Discussion: Health systems around the world are examining how to provide acute hospital-level care to older adults in
greater numbers with a fixed or shrinking hospital resource. This trial is the first large multi-site randomised trial of
geriatrician-led admission avoidance hospital at home, and will provide evidence on alternative models of healthcare for
older people who require hospital admission.
Trial registration: ISRCTN60477865: Registered on 10 March 2014. Trial Sponsor: University of Oxford. Version 3.1,
14/06/2016.
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Background
Older people are being admitted to hospital as an emer-
gency in increasing numbers [1]. From a system perspec-
tive this trend is not sustainable, and from a patient
perspective there are many reasons to question whether
a hospital is the best place of care for older adults with
frailty. There is some evidence to indicate that hospital
care might be potentially harmful to older people due to
a lack of mobility that can increase the risk of disability
from frailty [2]. The high cost of hospital-based care has
also been a major driver to innovate in an economic
climate that does not allow for the expansion of hospital
bed numbers to match the growth in admission numbers
[3]. Avoiding admission to hospital by the provision of
hospital-level care in the home is a model of healthcare
that is being considered in many countries [4, 5] as
hospitals deal with the rise in emergency admissions.
However, the scale to which these models of care have
transformed health systems is limited, reflecting the lack
of evidence to underpin decision-making.
A meta-analysis of randomised trials of admission
avoidance hospital at home is limited by the small num-
ber of small randomised controlled trials. The evidence
suggests that these types of service, that include the
option of transfer to hospital, may provide an effective
alternative to inpatient care for a select group of older
people who require hospital admission [4]. The lack of
data on cost-effectiveness also limits the extent to which
these types of service form part of a wider policy strategy
for acute hospital-level care. It is possible that avoiding
admission to hospital reduces the risk of delirium in
older people who require hospital-level healthcare.
Delirium, a frequent and serious complication in older
people who develop an acute illness, is associated with
adverse consequences which include increased risk of
hospital-acquired complications, new admission to
institutional care, new dementia, increased hospital
length of stay and increased mortality [6, 7].
Research objective
The primary objective is to undertake a multi-site rando-
mised trial to estimate the effectiveness of geriatrician-
led admission avoidance hospital at home in settings
where health and social care provision vary. Secondary
objectives are to investigate the incidence of delirium,
mortality, new long-term residential care, cognitive im-
pairment, activities of daily living, quality of life and
quality-adjusted survival, length of stay, readmission or
transfer to hospital, resource use (health and social care
and informal care), costs and cost-effectiveness. We will
also conduct a process evaluation to describe how the
geriatrician-led admission avoidance hospital at home
intervention is delivered, how this differs from inpatient
care, and how health and social care provision varies
between sites; this includes an interview study to explore
the experiences of patients and carers.
Methods/Design
The study protocol was developed using the SPIRIT
(Standard Protocol Items: Recommendations for Inter-
ventional Trials) Checklist (see Additional file 1).
Setting and sample
Participants are being recruited from primary care or an
acute hospital-based assessment unit in Aneurin Bevan
University Health Board; Bradford Teaching Hospitals
NHS Foundation Trust; Guy’s and St Thomas’s NHS
Foundation Trust, London; Royal Devon and Exeter
NHS Foundation Trust; Monklands Hospital, NHS
Lanarkshire; St John’s Hospital, NHS Lothian; Southern
Health and Social Care Trust, Northern Ireland; Belfast
Health and Social Care Trust, Northern Ireland. We are
recruiting older people with frailty who require a
hospital admission due to an acute change in health.
This might be due to acute functional deterioration, de-
lirium, falls and complex comorbidity. There is no
simple accepted definition of this population due to vari-
ation in the acute presenting illness. However, it is
agreed that the degree of prior disability is important
and that attempts to define this group should be
problem-based [8]. We will describe patients recruited
to this trial according to functional dependence, cogni-
tive impairment, comorbidity, history and/or presence of
delirium and presenting complaint (such as falls,
reduced mobility, confusion, carer strain).
Eligibility criteria
We are recruiting patients who meet the following eligi-
bility criteria for inclusion: (i) are 65 years and older, (ii)
are willing and able to give informed consent for partici-
pation in the study, (iii) have been referred to the
geriatrician-led admission avoidance hospital at home
service and would otherwise require hospital admission
for an acute medical event. The presence of a carer will
not be a requirement for enrolment and will depend on
the individual circumstances of the patient; this will be
at the discretion of the clinician responsible for the pa-
tient, as is current clinical practice in each centre. Partic-
ipants will be excluded if they have (i) an acute coronary
syndrome (this includes myocardial infarction and un-
stable angina and is characterised by cardiac chest pain
and associated with ECG changes), (ii) require an acute
surgical assessment, (iii) have a suspected stroke, (iv) are
receiving end of life care as part of a palliative care path-
way, (v) refuse admission to the geriatrician-led admis-
sion avoidance hospital at home, or are considered by
the clinical staff to be too high risk for home-based care,
for example those who are physiologically unstable, who
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are at risk to themselves or if the carer reports hospital
at home would not be acceptable, and (vi) patients living
in a residential setting.
Interventions
The intervention group is geriatrician-led co-ordinated,
multi-disciplinary healthcare in the home for people
who would otherwise be admitted to hospital (otherwise
known as admission avoidance hospital at home). Mem-
bers of the multi-disciplinary team (MDT) include
nurses, physiotherapists, occupational therapists and so-
cial workers (who might be part of the primary health
care team or dedicated staff ). The MDT implements
treatment and management recommendations, and if re-
quired refers to other services (e.g., older peoples’ men-
tal health services, diagnostic services, social workers,
dieticians, speech and language therapy, mental health
services, pharmacy support and outpatient follow-up).
Patients have access to inpatient care, general practi-
tioners and the primary healthcare team. The use of
intravenous infusions, administration of medication via a
pump and 24-hour care is available in some sites.
Healthcare is provided 7 days a week, admissions are re-
stricted to Monday to Friday in all but one site, from
0900 to early evening, and emergency medical cover is
available 24 hours a day.
The majority of participants (approximately 80%) who
are randomised to inpatient care (the control group) will
receive their care by a specialist-led geriatric service.
This variation will reflect the challenges of real-life sys-
tems and continued pressure on beds. Measures, in the
form of participating centres agreeing protocols, have
been taken to ensure that the features of usual care are
comparable.
Outcome measures
Primary outcome
We are collecting data for each patient on ‘living at
home’, defined as the inverse of death or living in a
residential care setting, at 6 months follow-up from
randomisation.
Secondary outcomes
At 6 months follow-up we are measuring:
 Incident and persistent delirium as defined by the
Confusion Assessment Method (CAM). The CAM is
a brief questionnaire that has been extensively used
in research for screening and case ascertainment
purposes [9].
 Cognitive impairment with the Montreal Cognitive
Assessment (MoCA), the normal range is from 30 to
26 [10].
 Activities of daily living, measured by the Barthel
Index [11].
 Mortality
 New long-term residential care
 Length of stay in admission avoidance hospital at
home and inpatient admission
 Readmission or transfer to hospital
 Health status (measured by the EuroQoL five
dimension (EQ5D) instrument to produce a single
index value for use in cost-effectiveness analysis) [12]
 Resource use
 Patient satisfaction using the Patient-Reported Experi-
ence questionnaire, developed by Picker Europe and
used in the National Audit of Intermediate Care [13].
 We are also collecting data for each patient on
‘living at home’ (the inverse of death or living in a
residential care setting) at 12 months follow-up.
Serious adverse event and adverse event reporting
The potential risks to participants of the research may
include a fall (either in the home or inpatient setting),
hospital-acquired infection for patients randomised to
inpatient admission, hospital admission for those rando-
mised to hospital at home, post-discharge hospitalization
and death for all participants. We categorise an adverse
event as serious if it results in death, is life-threatening,
requires hospitalisation or prolongation of existing in-
patient hospitalisation, results in persistent or significant
disability or incapacity, or is an important medical event.
Expected events for this patient population include falls,
pressure sores, hospital or community-acquired infec-
tion and transfer to hospital. All serious adverse events
(SAEs) which are related to administration of any of the
research procedures, and are an unexpected occurrence,
either observed by the recruiting clinician or reported by
the participant, will be recorded on the case report form
(CRF), and forwarded by the site to the trial manager
following assessment for seriousness by the site clinician.
As a minimum, the following information will be
recorded: description, date of onset, end date, assess-
ment of relatedness to the geriatrician-led admission
avoidance hospital at home intervention, other attribu-
tion/co-intervention and action taken. Follow-up infor-
mation will be provided as necessary. The chief
investigator (CI) or delegate will report SAEs, which in
the opinion of one of the clinical leads are ‘related’ and
‘unexpected’ when relating to the study procedures, to
the Research Ethics Committee (REC) within 15 working
days of the CI becoming aware of the event.
Recruitment
We have implemented a recruitment pathway that maps
to existing arrangements for referral. Eligible partici-
pants are identified from patients who are referred by
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their general practitioner to a single point of access for
admission to hospital at home, or who have been trans-
ferred from the Accident and Emergency Department to
an Acute Assessment Unit and are assessed as suitable
for hospital at home. At the point of referral to the trial
each participant is provided with a Participant Informa-
tion Leaflet that describes the research, and they are
provided with an opportunity to discuss their questions
and concerns about the research with a research nurse.
Each participant has the right to withdraw from the
study at any time, and if provided the reason for with-
drawal will be recorded in the CRF.
Randomisation procedure and concealment of allocation
The unit of randomisation is the individual participant,
who is randomly allocated using a 2:1 ratio (2 admission
avoidance hospital at home: 1 inpatient admission) by a
local member of the research team who accesses Sorti-
tion, the Oxford University’s Primary Care Clinical Trials
Unit’s validated in-house online randomisation system.
Telephone randomisation is used if sites do not have on-
line access. A computer-generated randomisation se-
quence is used, and randomisation is stratified by centre,
gender and by known cognitive decline [measured by
the Informant Questionnaire on Cognitive Decline in
the Elderly (IQCODE)] [14]. We have opted for a 2:1
randomisation ratio to deal with the concern expressed
by clinical leads that a 1:1 randomisation ratio would
place unmanageable pressure on the inpatient services.
The success of randomisation is being measured by the
number declining to be randomised or withdrawing im-
mediately after randomisation.
Data collection, management and analysis
Research nurses at each site collect data from partici-
pants, and from their caregivers if the caregiver is the
designated consultee, at baseline and 6 months after ran-
domisation and at 12 months for the primary outcome,
with the exception of an assessment of delirium which is
at 3 and 5 days, and at 1 month after recruitment (Fig. 1).
Each site completes a form to record if death has oc-
curred, with the date; these data are collected from the
medical records. Place of residence is recorded by the
research nurses at each follow-up visit. Data are col-
lected using a paper form, or directly to an electronic
pro forma on Open Clinica.
We collect data at baseline from the patient’s clin-
ical notes and from the clinical lead on the presenting
problem that requires admission to hospital, and
demographic information (age, education). We also
collect data on background cognitive status using the
IQCODE, a 16-item informant-based questionnaire,
which can also be completed by a carer [14]; incident
and persistent delirium measured by the CAM [9],
co-morbidity measured by the Charlson Index [15], activ-
ities of daily living measured by the Barthel Index [11],
current cognitive impairment measured by the MoCA
[10], health status measured by the EuroQol five-
dimension five-level instrument (EQ-5D-5 L) [12] and
major health service use (for example admission to
hospital, use of outpatient services and ambulances, home
care/help and respite stays in a residential setting) in the
6 months prior to their current illness. If the patient
appears to be burdened by the collection of baseline data
we use a two-stage approach, with core data (Short IQ
Code [14] and Confusion Assessment Method [9]) col-
lected prior to randomisation and following consent, and
the remaining data (Barthel Index [11], Charlson Co-
Morbidity Index [15], MoCA [10], EQ-5D-5 L [12] and
Health Resource Use Questionnaire) collected soon after
randomisation (Fig. 2).
At the 6-month follow-up point we collect data from
all patients on mortality, new long-term residential care,
cognitive impairment, activities of daily living, quality of
life, length of stay, readmission or transfer to hospital,
and on the number, type and duration of hospitalisa-
tions, the use of outpatient and day-case services, the
use of community-based health care services including
general practitioner consultations and practice-based
nursing, medications, respite care, social care including
admission to residential or nursing home, and amount
of informal care received over the preceding 6 months.
Unit costs will be attached to these resource volumes,
using National Health Service (NHS) reference costs,
Unit Costs of Health and Social Care (PSSRU), and
other national data sources. We will collect the costs of
the admission avoidance hospital at home intervention
in collaboration with providers, and include training
time and other elements. This is likely to vary between
centres and we aim to collect cost information from all
participating centres if possible. At 12 month follow-up
we will collect data on living at home (Table 1).
Process evaluation
We will complete a structured pro forma to record the
key features of the organisation and delivery of admission
avoidance hospital at home and of inpatient care, and any
local changes to policy and implementation. This will in-
clude reviewing care protocols, the method of assessing
the patient, and conversations with the staff delivering the
intervention. Once recruitment to the trial is established
approximately six patients and their carers (until data sat-
uration), from two or more hospital at home and inpatient
settings, will be invited to be interviewed at the point of
discharge or immediately after discharge from their
healthcare setting. Patients and carers will be selected to
include those with cognitive impairment, those who are
physically frail and who have experienced varied types of
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health crises (sudden onset of chronic illness, deterior-
ation in the context of multiple health problems and acute
exacerbation of a chronic condition) that will impact on
the recovery process. The interviews will assess the
process of care and how the healthcare they received
facilitated recovery, as well as relatives/caregivers per-
ceptions and experience of HAH and inpatient care.
Interviews will be recorded. We will also complete a
structured pro forma to record the key features of
the HAH with CGA intervention and of inpatient
care, this will include the use of care protocols, the
method of assessing the patient, and conversations
with the staff delivering the intervention.
Data management
We store all paper and electronic data in a secure envir-
onment, and refer to the participant by a trial number
and not by name, except for the signed consent form.
Fig. 1 Study flowchart
Shepperd et al. Trials  (2017) 18:491 Page 5 of 9
Fig. 2 Participant timeline
Table 1 Case report form
Study period
Baseline Day 3 Day 5 1 month 6 month 12 month
ENROLMENT
Eligibility screen X
Informed consent X
Screening log X
Randomisation X
ASSESSMENT
Assessment form X X X X X X
Demographics X
Presenting problem X
Place of assessment X X X X X X
Patient status (‘living at home’) X X X X X
Subsequent admissions X X
Adverse event log X X X X X
QUESTIONNAIRES
Barthel Index of Activities of Daily Living X X
Confusion Assessment Method (CAM) X X X X
Charlson Co-morbidity Index X X
Health Service Use Questionnaire X X
Short Form of the Informant Questionnaire on
Cognitive Decline in the Elderly (Short IQCODE)
X
Montreal Cognitive Assessment (MoCA) X X
EuroQol five-dimension five-level (EQ-5D-5 L) X X
Patient feedback form X
Difficulties in Questionnaire completion Form X X X X X
MISCELLANEOUS
Death form Completed on patient death
Discontinuation form Completed when a patient withdraws or is lost to follow-up
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We follow the standard operating procedures of the
University of Oxford Primary Care Clinical Trials Unit,
which are fully compliant with the Data Protection Act
and Good Clinical Practice (GCP). No-one outside the
study team has access to either the CRFs or the data-
base; members of the research team can access patient
identifiable data in order to collect follow-up data. Dir-
ect access will be granted to authorised representatives
from the sponsor and host institution for monitoring
and/or audit of the study to ensure compliance with reg-
ulations. Staff at each site enters data directly to a secure
laptop or computer or on paper versions of the CRF and
questionnaires. Data from paper forms are double en-
tered. Researchers from each site are asked to check data
for completeness prior to returning, for those sites en-
tering data directly into the database internal validation
checks are run for each data field. Any inconsistencies
and missing data are highlighted as queries which are
then returned to the site to be resolved. With regards
paper CRFs, the same checks are applied once the data
managers have performed the double data entry. Data
queries are returned to sites for resolution on a regular
basis. Interviews will be audio recorded, fully transcribed
and entered into NVivo software. Field notes pertaining
to the physical, social and care environment of the home
setting will also be managed and analysed. All audio re-
cordings and field notes will be stored safely in confiden-
tial conditions and electronic data in a secure, protected
environment.
Study oversight
The overall supervision of the trial is carried out by the
Trial Steering Committee. An independent Data
Monitoring Committee meets every 6 months to review
trial progress and data, this includes all SAE reports.
The sponsor is the University of Oxford.
Statistical methods
Sample size
We calculated the sample size for the primary outcome
‘living at home’ (the inverse of death or living in a resi-
dential care setting) at 6 months follow-up, for a 2:1 ran-
domisation ratio with two-thirds randomised to
admission avoidance hospital at home and one-third to
inpatient admission. Several sources informed our esti-
mate of effect size, these included an audit of 750 pa-
tients who received admission avoidance hospital at
home in Lanarkshire, and the summary estimate from a
Cochrane Review of admission avoidance hospital at
home that was published in 2008 [16]. Our proposed
study effect estimate is based on a control group (in-
patient admission) event rate at 12 months of 50% living
in a residential setting, with a 10% reduction to 40% in
the admission avoidance hospital at home group, equal
to a relative risk of 0.8 which lies towards the top end of
the 95% confidence interval (CI) for the pooled estimate
reported in the Cochrane Review [16]. We have calcu-
lated that to achieve 90% power at a significance level of
0.05, we will need to recruit 1350 participants to detect
a 10% absolute difference. The estimated recruitment
rate allows 15% attrition resulting in a projected sample
size of 1552. We have re-examined the sample size
calculation using an estimate of the intra-cluster correl-
ation (ICC) of 0.005, this would provide 88% power to
detect the assumed effect size of RR = 80%, for a two-
tailed alpha of 0.05.
Analysis
We will analyse the data using an intention-to-treat ana-
lysis and based on a mixed effect model adjusting for re-
cruitment centre (random effects) and individual patient
characteristics. For the primary outcome of living at
home 6 months, the primary analysis we will use a
mixed-effect logistic regression model including data
available on all randomised patients at 6 months and
12 months follow-up, adjusting for recruitment centre,
gender, and IQCODE score at baseline. In the model,
participants and centres will be fitted as random effect,
and time and treatment as fixed effect. We will fit an
interaction term between time and intervention group
so that possible differences of intervention effect could
be assessed at each time point. Although, the method
has the advantage of implicitly accounting for the data
missing at random mechanism, we will also assess the
impact of missing data on the primary analysis by
carrying out sensitivity analyses based on imputing
(multiple imputation) the missing values. We will use
similar models for all binary outcomes (presence of
delirium, cognitive impairment, etc.), and will use
equivalent models for continuous outcomes (e.g. nor-
mal distribution). We expect length of stay to be
highly skewed so other parametric models might be
required for this, and in the case of poor fit we will
use simple non-parametric tests (non-adjusted) for
this outcome. We have planned one subgroup analysis
of the effect of care setting (home versus hospital) on
the incidence of delirium in people who are cogni-
tively impaired (defined by the MoCA) [10].
Economic analysis
We will calculate the costs in each arm of the study on
an intention-to-treat basis, and will report these from a
health and social care perspective; in addition we will
quantify and value the cost of informal care. We will cal-
culate quality-adjusted life years from the responses to
the EQ-5D using the UK “tariff”, and use linear
interpolation between baseline and 6-month values and
adjusting for within-trial mortality. We will collect
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resource-use information on health and social care ser-
vices used, including the organisation and delivery of the
interventions, hospital inpatient stays and procedures,
outpatient and day-case use, hospital at home durations,
other consultations (including general practitioner and
community nurse consultations), medications, adverse
events, admission to respite care and long-term care and
use of other social care. Resource use volumes will be
multiplied by appropriate national unit costs such as
NHS Reference Costs to derive a cost per participant.
We will use an average cost in the main analysis, and in-
formation on variability will be used in sensitivity
analyses and to explore the possible costs of generalising
the service nationally if proven to be cost-effective. We
will estimate the main cost-effectiveness measure as the
net cost per quality-adjusted life year gained, for the
within-trial period. In the event of a within-trial differ-
ence in mortality, we will estimate average life expect-
ancy using information from life tables and relevant
cohort studies, and estimate quality-adjusted life years
gained/lost. We will handle uncertainty concerning the
reported cost-effectiveness ratio using the non-
parametric bootstrap and will report cost-effectiveness
acceptability curves, scatters on the cost-effectiveness
plane, and 95% confidence intervals (using the percentile
method) around the net benefit statistic. We will
conduct a sensitivity/scenario analyses for different cost
perspectives, and these will include analyses in which
the costs of admission avoidance hospital at home and
inpatient care are allowed to vary across a range ob-
served in the study, and analyses in which informal care
costs are excluded or included.
Analysis of the key features of contextual data
A narrative, descriptive account of the organization of
services at each centre will be produced drawing on data
collected from individual sites to populate a structured
pro forma; this will include an events log (that will in-
clude discussions with staff ) and formal documents re-
lating to organisation and delivery. We will focus on the
dimensions of the different settings and services, and
any changes to staffing and service organisation that
might impact on the delivery of healthcare (e.g., a reduc-
tion in geriatrician input; ward re-organisation/closures;
expansion/contraction of the scope of admission avoid-
ance hospital at home). We will compare sites and
services, and develop hypotheses to explore patterns of
variation in trial outcomes.
Analysis of qualitative interviews with patients and caregivers
We will use a grounded theory analytic approach in the
qualitative study, combining simultaneous data collec-
tion and analysis, constant comparison and search for
negative cases. The rationale for the adoption of a
grounded theory approach to analysis is twofold. First,
the approach is flexible yet systematic and robust
through the use of iterative, simultaneous data collection
and analysis, constant comparison, search for native
cases and memo writing to generate concepts and cat-
egories as well as their properties and dimensions
through the coding process. A second important feature
is a focus on context and process. This approach will
provide a more robust, systematic and in-depth ap-
proach to addressing issues of context and process, crit-
ical in this study. Our coding process will generate
elements that can be grouped into concepts and then
into higher order categories, which will form the basis of
our theory of patients’ perception of recovery and the
factors contributing to it (e.g., personal and social re-
sources, content and process of service delivery). We
will recruit additional respondents based on key features
to test out aspects of our developing grounded theory
(via theoretical sampling).
Discussion
The research outlined in this protocol is of increasing
importance given the current focus of policy in a
number of countries, including the UK, on providing co-
ordinated care for older people (including those with
cognitive impairment) that is closer to home. Further-
more, if a benefit of a reduced incidence of delirium is
confirmed by the results of this randomised controlled
trial there will be significant implications for vulnerable
patients with reduced functional and cognitive decline.
Trial status
Recruitment is ongoing
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